Illumina parts ways with Grail, with divestiture complete

Nearly four years after first pitching its multibillion-dollar plan to obtain Grail, Illumina has cut (nearly) all ties with the cancer blood test developer.

The DNA sequencing giant has completed its spinoff of the company—closing the book on a saga spanning continents, courtrooms and Carl Icahn’s calls for changes in leadership.